Menopause, Oestrogen and Vaginal Elasticity: The Cause That Is Not Childbirth

Almost everything written about vaginal laxity treats it as something that happens during childbirth. Which leaves a large group of women unable to account for what they are noticing in their late forties: things feel looser, or drier, or both, and nothing recent explains it. Some had straightforward births decades ago. Some never gave birth at all.

The explanation is hormonal, and it is one of the less discussed parts of the menopause. Falling oestrogen changes vaginal tissue itself, not only its lubrication, and in the research menopause shows up as a cause of laxity in its own right. What follows is what that evidence supports, why dryness and reduced elasticity turn up together, and where to take it if you live in Scotland.

Menopause earns its place on the list of causes

In a cross-sectional study of 300 women, menopause came up significantly more often among those reporting vaginal laxity: 52.6 percent of them had been through it. Adjusted for the other factors in play, their odds were 2.23 times higher.

Hold on to the word adjusted. The effect remains once childbirth history is taken into account, so the figure tracks the hormonal change rather than the obstetric one it travels alongside.

Set it against the mechanical causes from the same study. Compared with women who had never given birth vaginally, the adjusted odds were 2.62 times higher after one vaginal birth and 7.14 times higher after more than one, and 59.1 percent of the women reporting laxity were multiparous. Childbirth is still the largest mechanical factor by a distance.

But 2.23 is not a rounding error, and unlike the others it is not a choice anyone makes. Laxity has been filed culturally as a birth injury, which leaves the woman who never gave birth, or who delivered without incident twenty years ago, with something she can feel and nothing to blame. Menopause is what she has been missing.

The tissue underneath, and what maintains it

Support here comes from two sources, and only one is trainable. The levator ani is the muscular one, a broad sheet slung across the base of the pelvis, most of its fibres built for a steady all-day resting tone rather than short hard efforts.

The other source is the endopelvic fascia, the connective tissue anchoring bladder, urethra, vagina and uterus to the walls of the pelvis: a mesh of collagen fibres interlaced with elastin, plus smooth muscle, fibroblasts and blood vessels. Collagen accounts for roughly 70 to 80 percent of connective tissue, and which type is present matters more than how much. Type I is the strength component. Type III is the elastic one, the reason tissue can stretch and return rather than simply deform. With elastin, these make up the extracellular matrix, the scaffolding that sits between cells.

Oestrogen decline is documented as linked to two things: atrophy of the genitourinary tissue, and altered expression of the genes governing that extracellular matrix. The second is the interesting one. Expression is which genes are actively read and acted on, so a shift there means the cells responsible for the scaffolding have changed what they do with it.

That is an association and should be labelled as one. A hormonal change and a tissue change have been documented alongside each other; the mechanism joining them has not been traced end to end in women, and anyone selling you the stronger version has gone past the evidence. It remains the only account that covers the woman whose pelvic floor has never been through anything.

Why the dryness and the looseness are one problem

Dryness is the symptom that gets named, being easier to notice and fractionally easier to say out loud. It is not, though, a separate midlife problem that has coincided with the other one. One tissue change produces both: the wall that lubricates is the wall that gives, and both properties rest on the same scaffolding.

So if you have been working up to mentioning the dryness, you do not need a second script for the rest of it. It is one appointment, and you have already drafted the opening line.

On examination, incidentally, laxity can show as a loss of firmness in the vaginal walls, weakened vaginal muscles and elongated labia. It is observable, not imagined.

A second line of evidence points at the same scaffolding

Genetics arrives in the same place from an entirely unrelated direction. Most of that work concerns pelvic organ prolapse rather than laxity, and the two should not be run together: prolapse means an organ descending, with a bulge you can see or feel, while laxity is a sensation of looseness with nothing descending. The genetics is still instructive about the tissue. Prolapse is strongly heritable, with twin studies attributing around 40 percent of the variance to genetics and a family history conferring roughly a 2.3 to 2.7 fold increase in risk. Two of the clearest signals are a variant in COL3A1, the gene for Type III collagen, and variants in FBLN5, an elastic-fibre gene; knockout-mouse models link both causally to dilation of the vaginal wall.

An inherited variant and a hormonal withdrawal are separate routes to one address: the collagen and elastin scaffold of the vaginal wall.

Common, and measurably not trivial

How common? The 300-woman study put self-reported laxity at 31 percent, and a larger mixed population of 2,621 women at 38 percent. Estimates across the wider literature scatter between 2 and 48 percent, which says more about the measuring than about women: laxity is reported, not measured.

Its effect, though, has been quantified, on three validated scales. In the same study, women describing their vagina as loose scored 17.0 on the ICIQ-VS vaginal symptoms measure against 6.8 for women describing it as neither loose nor tight. On sexual quality of life, 54.8 against 72.5. On sexual distress, 19.5 against 10.4. All three differences were statistically significant, and all three point the same way.

And almost nobody is being asked about it. RCOG-commissioned polling found 69 percent of UK women have never had an NHS professional speak to them about their pelvic floor. A common change, with a measurable effect on quality of life, arriving at the age it is most likely and going unmentioned, is precisely why the marketing tends to reach women before the explanation does.

Take it to your GP practice first

Menopause care in Scotland runs through your own GP practice, and that is where this belongs long before it goes near an aesthetic clinic. Two reasons.

The first is the honest limit of what you have just read. It connects falling oestrogen to changed tissue. It does not tell you how much of that change is recoverable, by what, or how quickly, and no figure exists in this evidence for what HRT or vaginal oestrogen does to elasticity specifically. Rather than round the story off with an invented one, put the question to someone who can weigh it against your own history.

The second is ruling things out, which matters more in midlife than at any other point. Bleeding after the menopause needs medical assessment, as does unexplained bleeding at any age, pelvic pain, persistent incontinence, unusual or foul-smelling discharge, or a sensation of heaviness or dragging, which suggests prolapse rather than laxity and is a different problem with different answers. Check your cervical screening is current while you are there: it is offered from 25 to 64, and in Scotland women aged 25 to 49 who test negative for high-risk HPV are invited every five years.

What the treatment evidence says, including about the treatment aimed at you

Search for a treatment and you will find laser and radiofrequency devices advertised directly at menopausal vaginal change, which makes what follows unusually pointed for a reader in your position.

Start with what nobody is entitled to claim. No energy-based device, laser, radiofrequency or HIFU, holds FDA approval or NICE endorsement for vaginal tightening or rejuvenation. In 2018 the FDA stated that safety and effectiveness for this indication have not been established, called vaginal rejuvenation an ill-defined, non-scientific commercial term, and wrote to seven manufacturers.

Then read the NICE assessment closely, because it was not a verdict on tightening in general. NICE examined transvaginal laser therapy for urogenital atrophy, which is this indication, yours. Its finding was that evidence on long-term safety and efficacy is inadequate in quality and quantity, and that the procedure should be used only in the context of research. RCOG took the same line. When the technology was tested rigorously, in a sham-controlled trial of fractionated CO2 vaginal laser in 85 women, laser and sham were no different at 12 months. Radiofrequency has less behind it again: the most recent meta-analysis rates its evidence insufficient.

Reported side effects are usually mild and short-lived: discomfort, redness, swelling, altered discharge, itching. Rarely they are not, with burns, scarring, chronic pain and loss of sensation all on record. Undiagnosed bleeding, active infection and untreated cervical abnormalities are reasons not to proceed at all, which is the second argument for a GP before a clinic.

One regulatory point specific to where you live. The licensing scheme for non-surgical cosmetic procedures under the Health and Care Act 2022 is an England measure, and it tells you nothing about what governs a clinic in Glasgow. Ask any clinic directly what it is regulated under, and what its practitioners are individually qualified and insured for, rather than assuming a scheme you read about nationally reaches you here.

This is not an argument for doing nothing. It is an argument for order: the GP conversation, then a clear understanding of what falling oestrogen has done to the tissue, then a sceptical look at anything sold as a fix. If the red flags are cleared and you want an assessment of where you stand, a consultation with us is a reasonable place to have it, provided you get a straight answer about what the evidence does and does not support. What you should not accept is the framing that something has gone wrong with you. Nothing has failed. A supply was withdrawn on schedule and the tissue registered it, which is biology behaving predictably rather than a body letting you down.